192 related articles for article (PubMed ID: 12354174)
21. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
[TBL] [Abstract][Full Text] [Related]
22. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
24. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
25. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
Semb AG; Holme I; Kvien TK; Pedersen TR
Rheumatology (Oxford); 2011 Feb; 50(2):324-9. PubMed ID: 20884656
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
[TBL] [Abstract][Full Text] [Related]
27. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
[TBL] [Abstract][Full Text] [Related]
28. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
Durazzo AE; Machado FS; Ikeoka DT; De Bernoche C; Monachini MC; Puech-Leão P; Caramelli B
J Vasc Surg; 2004 May; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
[TBL] [Abstract][Full Text] [Related]
29. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.
Semb AG; Kvien TK; DeMicco DA; Fayyad R; Wun CC; LaRosa JC; Betteridge J; Pedersen TR; Holme I
Arthritis Rheum; 2012 Sep; 64(9):2836-46. PubMed ID: 22576673
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
32. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
33. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
34. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
[TBL] [Abstract][Full Text] [Related]
35. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Gresser U; Gathof BS
Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
[TBL] [Abstract][Full Text] [Related]
36. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Schwartz GG; Oliver MF; Ezekowitz MD; Ganz P; Waters D; Kane JP; Texter M; Pressler ML; Black D; Chaitman BR; Olsson AG
Am J Cardiol; 1998 Mar; 81(5):578-81. PubMed ID: 9514453
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
38. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Strandberg TE; Holme I; Faergeman O; Kastelein JJ; Lindahl C; Larsen ML; Olsson AG; Pedersen TR; Tikkanen MJ;
Am J Cardiol; 2009 May; 103(10):1381-5. PubMed ID: 19427432
[TBL] [Abstract][Full Text] [Related]
39. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
40. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Stefanadi E; Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Vavuranakis E; Triantafyllou G; Marinou K; Tsioufis C; Papageorgiou N; Latsios G; Stefanadis C
Int J Cardiol; 2009 Apr; 133(2):266-8. PubMed ID: 18187214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
